

Zahid H Siddik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5665869/publications.pdf>

Version: 2024-02-01

34
papers

4,257
citations

411340

20
h-index

536525

29
g-index

35
all docs

35
docs citations

35
times ranked

8271
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin: mode of cytotoxic action and molecular basis of resistance. <i>Oncogene</i> , 2003, 22, 7265-7279.	2.6	2,838
2	Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. <i>Oncogene</i> , 2005, 24, 2929-2943.	2.6	231
3	Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. <i>Analytical Biochemistry</i> , 1987, 163, 21-26.	1.1	137
4	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 3770-3780.	3.2	128
5	Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. <i>Seminars in Cancer Biology</i> , 2019, 58, 65-79.	4.3	94
6	Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3345-3352.	0.8	81
7	Recent Developments in Texaphyrin Chemistry and Drug Discovery. <i>Inorganic Chemistry</i> , 2013, 52, 12184-12192.	1.9	65
8	Elevated Glutathione Levels Confer Cellular Sensitization to Cisplatin Toxicity by Up-Regulation of Copper Transporter hCtr1. <i>Molecular Pharmacology</i> , 2008, 74, 697-704.	1.0	63
9	Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 12626-12631.	7.2	61
10	New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. <i>Oncotarget</i> , 2017, 8, 490-505.	0.8	61
11	Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. <i>Biochemical Pharmacology</i> , 2012, 83, 1049-1062.	2.0	60
12	ATP11B mediates platinum resistance in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2119-2130.	3.9	56
13	Chemical and Biological Studies on a Series of Novel (trans-(1R,2R)-,trans-(1S,2S)-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 267 1997, 40, 112-116.	2.9	52
14	The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. <i>Gynecologic Oncology</i> , 2011, 122, 402-409.	0.6	49
15	Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7021-7029.	3.3	42
16	Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 709-718.	1.2	29
17	A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. <i>MedChemComm</i> , 2012, 3, 1275.	3.5	27
18	Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1701-1705.	1.0	25

#	ARTICLE	IF	CITATIONS
19	Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. Journal of Inorganic Biochemistry, 1994, 54, 39-47.	1.5	20
20	Photoinduced Reduction of PtIV within an Anti-Proliferative PtIV-Texaphyrin Conjugate. Chemistry - A European Journal, 2014, 20, n/a-n/a.	1.7	17
21	Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: Synthesis and comparison with carboplatin in normal and Pt-resistant cell lines. Dalton Transactions, 2009, , 10834.	1.6	16
22	Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget, 2017, 8, 10905-10918.	0.8	15
23	Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie, 2016, 128, 12816-12821.	1.6	13
24	Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Molecular Cancer Research, 2017, 15, 328-339.	1.5	12
25	Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog. Prostate, 2005, 62, 91-100.	1.2	10
26	Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemotherapy and Pharmacology, 2010, 65, 427-436.	1.1	10
27	Cisplatin Resistance. , 2006, , 283-307.		7
28	Apoptosis in Cancer. , 2014, , 357-390.		4
29	Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill. Molecular Pharmacology, 2020, 97, 237-249.	1.0	4
30	Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents. Cancer Chemotherapy and Pharmacology, 2020, 85, 1129-1140.	1.1	2
31	Drug Resistance and the Tumor Suppressor p53: The Paradox of Wild-Type Genotype in Chemorefractory Cancers. , 2009, , 209-231.		2
32	Frontispiz: Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie, 2016, 128, .	1.6	0
33	Frontispiece: Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie - International Edition, 2016, 55, .	7.2	0
34	Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy. , 2010, , 199-213.		0